Core Laboratories (CLB) Common Equity (2022 - 2026)

Core Laboratories has reported Common Equity for 5 years, with the latest figure at $268.9 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 5.89% year-over-year to $268.9 million; the trailing twelve-month figure through Mar 2026 stood at $268.9 million (up 5.89% YoY), and the FY2025 full-year result was $266.0 million, up 5.42% from the prior year.
• Common Equity for Q1 2026 stood at $268.9 million, up from $266.0 million in the prior quarter.
• The five-year high for Common Equity was $277.4 million in Q3 2025, with the low at $173.8 million in Q2 2022.
• Historically, Common Equity has averaged $233.7 million across 5 years, with a median of $241.6 million in 2024.
• Annual changes were most pronounced in 2023 — Common Equity gained 26.38% — and 2025, when it advanced 5.42%.
• Core Laboratories' Common Equity stood at $183.5 million in 2022, then increased by 22.26% to $224.4 million in 2023, then grew by 12.45% to $252.3 million in 2024, then rose by 5.42% to $266.0 million in 2025, then grew by 1.09% to $268.9 million in 2026.
• The last three Common Equity figures came in at $268.9 million (Q1 2026), $266.0 million (Q4 2025), and $277.4 million (Q3 2025), per Business Quant data.